Clinical Trial

Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC)

Name: Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC) — clinical trial record (NCT07555587)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase Ib, open-label study to evaluate safety and efficacy of NRT6008 in combination with standard-of-care chemotherapy in patients with unresectable Locally Advanced Pancreatic Carcinoma (LAPC).

Trial Details

NCT Number	NCT07555587
Lead Sponsor	NRT MedTech Australia Pty Ltd
Conditions	Unresectable Locally Advanced Pancreatic Carcinoma
Enrollment	10 participants
Start Date	2026-09
Primary Completion	2028-08 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-29